- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT03049397
Enhancing Connections Program in Improving Family Adjustment in Patients With Incurable Cancer
Family Functioning and Bereavement Outcomes Following the Enhancing Connections Program in Palliative Care
Обзор исследования
Статус
Вмешательство/лечение
Подробное описание
PRIMARY OBJECTIVES:
I. Test the feasibility of the study protocol in advanced cancer patients and co-parents (recruitment/retention, dosage and fidelity of the intervention; program acceptability of program; and logistics).
II. Evaluate the short-term impact of the program on the diagnosed parents', co-parents' and children's adjustment and family functioning using a within group design (pre- and posttest design).
III. Compare outcomes from the Enhancing Connections Palliative Program with similar outcomes obtained from the completed phase III trial (between group design) for the patients and children outcomes.
IV. Evaluate the longer term impact of the program on the co-parents' and children's adjustment, including bereavement outcomes when appropriate, using a within and across group design (pre- and posttest design).
OUTLINE:
Patients and co-parents participate in the Enhancing Connections program consisting of 5 sessions over 1 hour each in the clinic or over the telephone. Session topics include managing cancer-related emotions when talking to children, developing deep listening skills, initiating difficult cancer-related conversations with children, interpreting a child's behavior, recognizing newly acquired gains from the program, and identifying available resources that can be used after program completion.
After completion of the study, participants are followed-up at 6 months.
Тип исследования
Регистрация (Действительный)
Фаза
- Непригодный
Контакты и местонахождение
Места учебы
-
-
Washington
-
Seattle, Washington, Соединенные Штаты, 98109
- Fred Hutch/University of Washington Cancer Consortium
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
PATIENTS
- Ages 25-65 years
- Have a diagnosis of incurable cancer of any type; at any time in the diagnosis as long as they have at least a 4 month life expectancy based on the opinion of the attending physician
- Read and write English among their languages of choice
- Parent must live at least 50% of the time in the home and have a child 5-17 years old living at home who has been told their parent's cancer diagnosis
CO-PARENTS
- Co-parents must reside with the consenting eligible cancer participant (and child) at least 50% of the time and be actively participating in the care of the child
- If a biological parent lives in the home, and is physically well themselves, this person must be the co-parent
- If a biological parent does not live in the home (or has died), the co-parent does not have to be a biological parent; therefore, co-parents may be step-parents, lesbian, gay, bi-sexual or transgender (LGBT) partners, grandparents, aunts, uncles, etc if they otherwise meet eligibility criteria
- He or she can read and write English among their languages of choice and agrees to attend the patient intervention sessions in person or by telephone
CHILDREN
- The patient and co-parent must agree to focus on the same child throughout the study and consent to have the child participate before the child's assent will be sought
- Children aged 5-13 years of age will participate with a waiver of assent
- Children aged 14-17 will assent to participate in the research study by signing a separate assent form
- Children of formal assenting age will be eligible to participate if they can read and write English among their languages of choice
ALL PARTICIPANTS
- Participants must live within 35 miles of the University of Washington, Seattle, WA to receive the in-person version of the intervention
- Parents and co-parents selecting the telephone version of the intervention may live any distance from the University of Washington
Exclusion Criteria:
- Patients will be excluded if they are enrolled in hospice at time of enrollment; however, they will be allowed to continue in the study if they enroll in hospice after beginning the study
- The triad will be ineligible if any member lives in the home less than 50% of the time
- If any member of the triad retracts consent or assent prior to completion of the post-intervention surveys, then all members will be excluded from the study thereafter
- The child will be excluded if he or she has learning challenges as assessed by the patient or co-parent; patients and co-parents will be instructed to consider any formal diagnoses of a learning disability of the presence of an Individual Education Plan (IEP) when making this assessment
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Поддерживающая терапия
- Распределение: Н/Д
- Интервенционная модель: Одногрупповое задание
- Маскировка: Нет (открытая этикетка)
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: Supportive Care (Enhancing Connections program)
Patients and co-parents participate in the Enhancing Connections program consisting of 5 sessions over 1 hour each in the clinic or over the telephone.
Session topics include managing cancer-related emotions when talking to children, developing deep listening skills, initiating difficult cancer-related conversations with children, interpreting a child's behavior, recognizing newly acquired gains from the program, and identifying available resources that can be used after program completion.
|
Дополнительные исследования
Complete Enhancing Connections program
|
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Feasibility of the Enhancing Connections program in advanced cancer patients and co-parents
Временное ограничение: Up to 2 years
|
Recruitment and retention of all triads will be monitored.
Dosage and fidelity will be monitored for each intervention session.
Program acceptability (per session, overall, duration of program, interval between intervention sessions) will be assessed from a debriefing interview.
For logistics four areas will be monitored: rate of receipt of mailed materials both to participants and from participants; duration and type (whether telephone or in-person) of intervention sessions; rate of success in scheduling and completing intervention sessions with patient and co-parent; and quality of data on baseline, post-intervention and follow-up measures.
|
Up to 2 years
|
|
Change in adjustment and family functioning
Временное ограничение: Baseline to 6 months
|
Descriptive statistics (e.g.
means, medians) will be used to describe the Enhancing Connections palliative care population.
Parents', co-parents and children's baseline scores [parent-reported] on standardized questionnaires will be compared with post-intervention and 6 month follow-up scores on the same measures.
|
Baseline to 6 months
|
|
Outcomes from the Enhancing Connections Palliative Program as measured by the Child Behavior Check List
Временное ограничение: Up to 2 years
|
Linear mixed modeling based on Maximum Likelihood Estimation will be used to test the differences between the Child Behavior Check List results for the Enhancing Connections Palliative Program and the completed phase III trial (EC-R01).
|
Up to 2 years
|
|
Change in adjustment as measured by post-traumatic growth scores
Временное ограничение: Baseline to 6 months
|
Enhancing Connection Palliative Program parents', co-parents' and children's post-traumatic growth scores will be compared with follow-up (6 month) scores on the same measure.
|
Baseline to 6 months
|
Соавторы и исследователи
Спонсор
Соавторы
Следователи
- Главный следователь: Elizabeth Loggers, Fred Hutch/University of Washington Cancer Consortium
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Действительный)
Завершение исследования (Действительный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Дополнительные соответствующие термины MeSH
Другие идентификационные номера исследования
- 9667 (Другой идентификатор: Fred Hutch/University of Washington Cancer Consortium)
- P30CA015704 (Грант/контракт NIH США)
- NCI-2016-01640 (Идентификатор реестра: CTRP (Clinical Trial Reporting Program))
- RG9218011 (Другой идентификатор: Fred Hutch/University of Washington Cancer Consortium)
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .
Клинические исследования Продвинутое злокачественное новообразование
-
Washington University School of MedicineExelixisРекрутингПродвинутая лейомиосаркома | Адипоцитарная саркома | Advanced LiposarcomaСоединенные Штаты
-
Yonsei UniversityЕще не набираютRAS/BRAF DILE-TYPE Advanced Corelectal Cancer PementКорея, Республика
-
Advanced BionicsЗавершенныйТяжелая или глубокая потеря слуха | у взрослых пользователей системы Advanced Bionics HiResolution™ Bionic Ear SystemСоединенные Штаты
-
Fudan UniversityРекрутингРадиоактивный йод-резист, дифференцированный рак щитовидной железы с помощью мутации NRA | Advanced PDTC или ATC с мутацией NRASКитай
-
National University Hospital, SingaporeEDDC (Experimental Drug Development Centre), A*STAR Research EntitiesРекрутингС MSS/pMMR Advanced, платинорезистентным раком яичниковСингапур
-
SynthekineРекрутингНемелкоклеточный рак легкого | Продвинутая солидная опухоль | Необработанный Advanced NSCLC | 1 -я строка NSCLCСоединенные Штаты
Клинические исследования Администрация анкеты
-
Assistance Publique - Hôpitaux de ParisЗавершенныйБолезнь Паркинсона | Дистонические расстройства | Функциональное двигательное расстройствоФранция
-
Far Eastern Memorial HospitalЗавершенный
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationРекрутингРасстройства поведения | Расстройство аутистического спектраШвейцария